How To Better Support Individuals With Bipolar 1 Disorder

·1 min read

Northampton, MA --News Direct-- Alkermes

We’re committed to listening to mental health providers and learning how we can better help them support individuals with bipolar 1 disorder.

Our survey of psychiatrists conducted with The Harris Poll & Depression and Bipolar Support Alliance – National Headquarters uncovered varying answers for why individuals may stop taking their medication.

About Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at

View additional multimedia and more ESG storytelling from Alkermes on

View source version on

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting